Febit group

Heidelberg, Germany

Febit group

Heidelberg, Germany
Time filter
Source Type

Lange J.,Febit Group | Leidinger P.,Saarland University | Oehler T.,Febit Group | Keller A.,Febit Group | And 2 more authors.
Geburtshilfe und Frauenheilkunde | Year: 2010

The value of biomarkers for diagnostic and prognostic assessments has become well established in medicine. Technological advances, especially in genomics and transcriptomics, allow researchers to obtain molecular fingerprints of human diseases such as cancers, and fine-tune patient classification according to the detected molecular changes. MicroRNAs (miRNAs) are endogenous noncoding small RNAs negatively regulating the translation of coding messenger RNAs (mRNAs) in a sequence-specific manner. The role of mi-RNAs in pathogenesis and the power to associate expression changes with disease states underscores their value as molecular biomarkers. Automated miRNA biomarker profiling using febit's microfluidic microarray technology is a promising approach for diagnostic tests, permitting highly sensitive analysis to be performed even with limited clinical sample materials such as blood or other body fluids. Testing for marker miRNAs, for example in breast or ovarial cancer, using established biochips contributes to the development of predictive miRNA signatures for the accurate diagnosis, monitoring or prognosis of diseases. This has been proven in research studies where blood-based miRNA profiling on febit?s Geniom RT Analyzer resulted in accurate classification of patients. The technology presented here provides the basis for early diagnostic testing, detection and assessment of disease progression, all of which are essential for successful disease management, especially in tumor patients where timely therapeutic interventions are extremely critical. © Georg Thieme Verlag KG Stuttgart.

Matzas M.,Febit Group | Stahler P.F.,Febit Group | Kefer N.,Febit Group | Siebelt N.,Febit Group | And 9 more authors.
Nature Biotechnology | Year: 2010

The construction of synthetic biological systems involving millions of nucleotides is limited by the lack of high-quality synthetic DNA. Consequently, the field requires advances in the accuracy and scale of chemical DNA synthesis and in the processing of longer DNA assembled from short fragments. Here we describe a highly parallel and miniaturized method, called megacloning, for obtaining high-quality DNA by using next-generation sequencing (NGS) technology as a preparative tool. We demonstrate our method by processing both chemically synthesized and microarray-derived DNA oligonucleotides with a robotic system for imaging and picking beads directly off of a high-throughput pyrosequencing platform. The method can reduce error rates by a factor of 500 compared to the starting oligonucleotide pool generated by microarray. We use DNA obtained by megacloning to assemble synthetic genes. In principle, millions of DNA fragments can be sequenced, characterized and sorted in a single megacloner run, enabling constructive biology up to the megabase scale. © 2010 Nature America, Inc. All rights reserved.

Schmitt J.,Saarland University | Backes C.,Saarland University | Nourkami-Tutdibi N.,Saarland University | Leidinger P.,Saarland University | And 7 more authors.
BMC Genomics | Year: 2012

Background: Blood-born miRNA signatures have recently been reported for various tumor diseases. Here, we compared the miRNA signature in Wilms tumor patients prior and after preoperative chemotherapy according to SIOP protocol 2001.Results: We did not find a significant difference between miRNA signature of both groups. However both, Wilms tumor patients prior and after chemotherapy showed a miRNA signature different from healthy controls. The signature of Wilms tumor patients prior to chemotherapy showed an accuracy of 97.5% and of patients after chemotherapy an accuracy of 97.0%, each as compared to healthy controls.Conclusion: Our results provide evidence for a blood-born Wilms tumor miRNA signature largely independent of four weeks preoperative chemotherapy treatment. © 2012 Schmitt et al.; licensee BioMed Central Ltd.

Keller A.,Biomarker Discovery Center | Keller A.,Saarland University | Leidinger P.,Saarland University | Bauer A.,German Cancer Research Center | And 44 more authors.
Nature Methods | Year: 2011

In a multicenter study, we determined the expression profiles of 863 microRNAs by array analysis of 454 blood samples from human individuals with different cancers or noncancer diseases, and validated this 'miRNome' by quantitative real-time PCR. We detected consistently deregulated profiles for all tested diseases; pathway analysis confirmed disease association of the respective microRNAs. We observed significant correlations (P = 0.004) between the genomic location of disease-associated genetic variants and deregulated microRNAs. © 2011 Nature America, Inc. All rights reserved.

Loading Febit group collaborators
Loading Febit group collaborators